LONG-TERM, REAL-WORLD TREATMENT PERSISTENCE AND MUCOSAL HEALING RATES WITH VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Stefan Schreiber  ¹     Patricia Biedermann  ²     Rebecca J. Brown  ³     Marlies Neuhold  ³     Steve Wisseh  ^4    
1 Institute of Clinical Molecular Biology and Clinic for Internal Medicine, Kiel University, Kiel, Germany
² Takeda Pharmaceuticals International AG, Zurich, Switzerland
³ PHMR Ltd, London, United Kingdom
⁴ Takeda Pharmaceutical Company Limited, Cambridge, United States

Topic
IBD

Session
Meet the giants at the poster (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)